Search Results - "GOLDBERG, Richard M"

Recent Therapeutic Advances in the Treatment of Colorectal Cancer by Ciombor, Kristen K, Wu, Christina, Goldberg, Richard M

“…Metastatic colorectal cancer is a prevalent disease for which novel targeted therapies and biologically based combinations are under development. Cytotoxic…”
Get full text

Platinum neurotoxicity pharmacogenetics by McWhinney, Sarah R, Goldberg, Richard M, McLeod, Howard L

“…Cisplatin, carboplatin, and oxaliplatin anticancer drugs are commonly used to treat lung, colorectal, ovarian, breast, head and neck, and genitourinary…”
Get full text

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial by Grothey, Axel, MD, Cutsem, Eric Van, Prof, Sobrero, Alberto, MD, Siena, Salvatore, MD, Falcone, Alfredo, MD, Ychou, Marc, MD, Humblet, Yves, MD, Bouché, Olivier, MD, Mineur, Laurent, MD, Barone, Carlo, MD, Adenis, Antoine, MD, Tabernero, Josep, MD, Yoshino, Takayuki, MD, Lenz, Heinz-Josef, MD, Goldberg, Richard M, MD, Sargent, Daniel J, PhD, Cihon, Frank, MS, Cupit, Lisa, MD, Wagner, Andrea, MD, Laurent, Dirk, DrMed

“…Summary Background No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but…”
Get full text

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers by Salem, Mohamed E, Puccini, Alberto, Grothey, Axel, Raghavan, Derek, Goldberg, Richard M, Xiu, Joanne, Korn, W Michael, Weinberg, Benjamin A, Hwang, Jimmy J, Shields, Anthony F, Marshall, John L, Philip, Philip A, Lenz, Heinz-Josef

“…The efficacy of immunotherapy varies widely among different gastrointestinal cancers. Response to immune checkpoint inhibitors is shown to correlate with tumor…”
Get full text

Relationship between MLH1, PMS2, MSH2 and MSH6 gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumors by Salem, Mohamed E., Bodor, J. Nicholas, Puccini, Alberto, Xiu, Joanne, Goldberg, Richard M., Grothey, Axel, Korn, W. Michael, Shields, Anthony F., Worrilow, William M, Kim, Edward S., Lenz, Heinz‐Josef, Marshall, John L., Hall, Michael J.

“…Microsatellite instability‐high (MSI‐H) and tumor mutational burden (TMB) are predictive biomarkers for immune‐checkpoint inhibitors (ICIs). Still, the…”
Get full text

Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 by FRANKO, Jan, QIAN SHI, GOLDMAN, Charles D, POCKAJ, Barbara A, NELSON, Garth D, GOLDBERG, Richard M, PITOT, Henry C, GROTHEY, Axel, ALBERTS, Steven R, SARGENT, Daniel J

“…Symptoms and complications of metastatic colorectal cancer (mCRC) differ by metastatic sites. There is a paucity of prospective survival data for patients with…”
Get full text

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas by Blazer, Marlo, Wu, Christina, Goldberg, Richard M., Phillips, Gary, Schmidt, Carl, Muscarella, Peter, Wuthrick, Evan, Williams, Terrence M., Reardon, Joshua, Christopher Ellison, E., Bloomston, Mark, Bekaii-Saab, Tanios

“…Background For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown…”
Get full text

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial by Tabernero, Josep, Dr, Lenz, Heinz-Josef, Prof, Siena, Salvatore, MD, Sobrero, Alberto, MD, Falcone, Alfredo, Prof, Ychou, Marc, Prof, Humblet, Yves, Prof, Bouché, Olivier, Prof, Mineur, Laurent, MD, Barone, Carlo, Prof, Adenis, Antoine, Prof, Yoshino, Takayuki, MD, Goldberg, Richard M, Prof, Sargent, Daniel J, Prof, Wagner, Andrea, MD, Laurent, Dirk, MD, Teufel, Michael, PhD, Jeffers, Michael, PhD, Grothey, Axel, Prof, Van Cutsem, Eric, Prof

“…Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the…”
Get full text

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) by LEE KINDLER, Hedy, NIEDZWIECKI, Donna, PICUS, Joel, BHARGAVA, Pankaj, MAYER, Robert J, SCHILSKY, Richard L, GOLDBERG, Richard M, HOLLIS, Donna, SUTHERLAND, Susan, SCHRAG, Deborah, HURWITZ, Herbert, INNOCENTI, Federico, FRANCES MULCAHY, Mary, O'REILLY, Eileen, WOZNIAK, Timothy F

“…The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients…”
Get full text

Hypermutated Tumors and Immune Checkpoint Inhibition by Ciombor, Kristen K., Goldberg, Richard M.

“…Microsatellite instability-high/DNA mismatch repair deficient tumors are found across the cancer spectrum and often harbor markedly increased numbers of…”
Get full text

Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy by SINICROPE, Frank A, MAHONEY, Michelle R, SMYRK, Thomas C, THIBODEAU, Stephen N, WARREN, Robert S, BERTAGNOLLI, Monica M, NELSON, Garth D, GOLDBERG, Richard M, SARGENT, Daniel J, ALBERTS, Steven R

“…The association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and…”
Get full text

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 by ALLEGRA, Carmen J, YOTHERS, Greg, O'REILLY, Seamus, CHU, Luis, AZAR, Catherine A, LOPA, Samia, WOLMARK, Norman, O'CONNELL, Michael J, SHARIF, Saima, PETRELLI, Nicholas J, COLANGELO, Linda H, ATKINS, James N, SEAY, Thomas E, FEHRENBACHER, Louis, GOLDBERG, Richard M

“…The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the safety and efficacy of adding bevacizumab to modified…”
Get full text

Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence by Kelly, Hanna, Goldberg, Richard M

“…Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve response rate and prolong median survival over fluorouracil with…”
Get full text

The evolving role of radiation in pancreatic cancer by Malla, Midhun, Fekrmandi, Fatemeh, Malik, Nadia, Hatoum, Hassan, George, Sagila, Goldberg, Richard M, Mukherjee, Sarbajit

“…Pancreatic cancer is the fourth leading cause of cancer mortality in the United States. Chemotherapy in resectable pancreatic cancer has improved survival by…”
Get full text

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project by Sjoquist, Katrin M, Renfro, Lindsay A, Simes, R John, Tebbutt, Niall C, Clarke, Stephen, Seymour, Matthew T, Adams, Richard, Maughan, Timothy S, Saltz, Leonard, Goldberg, Richard M, Schmoll, Hans-Joachim, Van Cutsem, Eric, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Tournigand, Christophe, Punt, Cornelis J A, Koopman, Miriam, Hurwitz, Herbert, Heinemann, Volker, Falcone, Alfredo, Porschen, Rainer, Fuchs, Charles, Diaz-Rubio, Eduardo, Aranda, Enrique, Bokemeyer, Carsten, Souglakos, Ioannis, Kabbinavar, Fairooz F, Chibaudel, Benoist, Meyers, Jeffrey P, Sargent, Daniel J, de Gramont, Aimery, Zalcberg, John R

“…Abstract Background Estimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for clinical…”
Get full text

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers by Enzinger, Peter C, Burtness, Barbara Ann, Niedzwiecki, Donna, Ye, Xing, Douglas, Kathe, Ilson, David H, Villaflor, Victoria Meucci, Cohen, Steven J, Mayer, Robert J, Venook, Alan, Benson, 3rd, Al Bowen, Goldberg, Richard M

“…To determine the optimal chemotherapy backbone for testing in future US cooperative group studies for metastatic esophageal and gastroesophageal junction…”
Get full text

Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment by GROTHEY, Axel, SARGENT, Daniel, GOLDBERG, Richard M, SCHMOLL, Hans-Joachim

“…Fluorouracil (FU)-leucovorin (LV), irinotecan, and oxaliplatin administered alone or in combination have proven effective in the treatment of advanced…”
Get full text

The impact of ARID1A mutation on molecular characteristics in colorectal cancer by Tokunaga, Ryuma, Xiu, Joanne, Goldberg, Richard M., Philip, Philip A., Seeber, Andreas, Battaglin, Francesca, Arai, Hiroyuki, Lo, Jae Ho, Naseem, Madiha, Puccini, Alberto, Berger, Martin D., Soni, Shivani, Zhang, Wu, Chen, Sting, Hwang, Jimmy J., Shields, Anthony F., Marshall, John L., Baba, Hideo, Korn, W.Michael, Lenz, Heinz-Josef

“…ARID1A is a key subunit of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex which regulates dynamic repositioning of nucleosomes to repair DNA damage. Only…”
Get full text

Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years by SANOFF, Hanna K, CARPENTER, William R, SCHYMURA, Maria J, SCHRAG, Deborah, STÜRMER, Til, GOLDBERG, Richard M, MARTIN, Christopher F, FINE, Jason P, JACKSON MCCLEARY, Nadine, MEYERHARDT, Jeffrey A, NILAND, Joyce, KAHN, Katherine L

“…Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group…”
Get full text

Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2 by Haraldsdottir, Sigurdis, Rafnar, Thorunn, Frankel, Wendy L., Einarsdottir, Sylvia, Sigurdsson, Asgeir, Hampel, Heather, Snaebjornsson, Petur, Masson, Gisli, Weng, Daniel, Arngrimsson, Reynir, Kehr, Birte, Yilmaz, Ahmet, Haraldsson, Stefan, Sulem, Patrick, Stefansson, Tryggvi, Shields, Peter G., Sigurdsson, Fridbjorn, Bekaii-Saab, Tanios, Moller, Pall H., Steinarsdottir, Margret, Alexiusdottir, Kristin, Hitchins, Megan, Pritchard, Colin C., de la Chapelle, Albert, Jonasson, Jon G., Goldberg, Richard M., Stefansson, Kari

“…Lynch syndrome, caused by germline mutations in the mismatch repair genes, is associated with increased cancer risk. Here using a large whole-genome sequencing…”
Get full text